Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world’s greatest health challenges Tru...
Pharma service provider further expands offerings for clinical development and manufacturing Already 14 customer fills completed in the first quarter of...
Details of the events are as follows: Event: Event: BIO International ConventionDate: June 5-8, 2023Registration: https://www.bio.org/events/bio-internati...
Under the terms of the agreement, Acorda will receive an up-front payment of $2.5 million, a near term milestone payment of up to $6 million, $3 million up...
The life science track includes companies developing technology in the fields of drug discovery, pharmaceuticals, and therapeutics. The medical technologie...
Two newly published pieces indicate that the ophthalmology community is more broadly embracing myopia control and management, according to global cat...
Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22 – – Orders increased to $64.2M in 2QFY23; up 17% over 2QFY22 – –...
Catalent does not endorse TRC’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in response to this unsolic...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA)...
“We are thrilled to have established a partnership with Dr. Reddy’s while toripalimab’s global commercial network has been steadily expan...
Largely driven by increasing incidence of chronic and infectious diseases and growth in biotechnology and pharma industries, the global immunoassay market ...
Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS. Our ability to deliver ou...
OnKai, a US-based technology company, combines public healthcare and medical innovation experience with complex process digitalization, design thinking, an...
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients...
© 2025 Biopharma Boardroom. All Rights Reserved.
